Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Ofri Mosenzon's publication output changed over time?
ScholarIQpublication output · 2013–2020
Output grew0% over the shown period — from 1 works in 2013 to 1 in 2020.
1
1
1
3
5
1
201320142017201820192020
What are the most-cited papers on Ofri Mosenzon?
ScholarIQmost cited works
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca, Ofri Mosenzon, Eri Kato, Avivit Cahn, Michael G. Silverman, Thomas A. Zelniker, Julia Kuder, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Christian T. Ruff, Ingrid Gause‐Nilsson, Martin Fredriksson, Peter A. Johansson, Anna-Maria Langkilde, Marc S. Sabatine
New England Journal of Medicine. 20186,387 CitationsOPEN ACCESS
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica, Deepak L. Bhatt, Eugene Braunwald, Philippe Gabríel Steg, Jaime A. Davidson, Boaz Hirshberg, Peter Öhman, Robert Frederich, Stephen D. Wiviott, Elaine Hoffman, Matthew A. Cavender, Jacob A. Udell, Nihar R. Desai, Ofri Mosenzon, Darren K. McGuire, Kausik K. Ray, Lawrence A. Leiter, Itamar Raz
New England Journal of Medicine. 20133,486 CitationsOPEN ACCESS
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker, Stephen D. Wiviott, Itamar Raz, KyungAh Im, Erica L. Goodrich, Marc P. Bonaca, Ofri Mosenzon, Eri Kato, Avivit Cahn, Remo H.M. Furtado, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Marc S. Sabatine
The Lancet. 20182,848 Citations
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark, Kathleen Dungan, Freddy G. Eliaschewitz, Denise Reis Franco, Ole Kleist Jeppesen, Ildiko Lingvay, Ofri Mosenzon, Sue D. Pedersen, Cees J. Tack, Mette S. Thomsen, Tina Vilsbøll, Mark Warren, Stephen C. Bain
New England Journal of Medicine. 20191,969 CitationsOPEN ACCESS
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
Patrick M. O’Neil, Andreas L. Birkenfeld, Barbara McGowan, Ofri Mosenzon, Sue D. Pedersen, Sean Wharton, Charlotte Giwercman Carson, Cecilie H. Jepsen, Maria Kabisch, John Wilding
The Lancet. 2018813 Citations
Related on ScholarIQ
Alzheimer's Association of Israel
Institution
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Paper
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Paper
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Paper
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Paper
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
Paper